Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Resonance HealthASX:RHT +1.79% Cash-to-Debt is 0.66 as of Dec. 2025, which is 99% below its 10-year median of 48.63. The stock has 8 warning signs investors should review. Among 670 Healthcare Providers & Services companies, Resonance Health ranks worse than 53.73% on this metric.
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Resonance Health's cash to debt ratio for the quarter that ended in Dec. 2025 was 0.66.
If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, Resonance Healthcouldn't pay off its debt using the cash in hand for the quarter that ended in Dec. 2025.
The historical rank and industry rank for Resonance Health's Cash-to-Debt or its related term are showing as below:
ASX:RHT'
s Cash-to-Debt Range Over the Past 10 Years
Min: 0.66 Med: 48.63 Max: No Debt
Current: 0.66
During the past 13 years, Resonance Health's highest Cash to Debt Ratio was No Debt. The lowest was 0.66. And the median was 48.63.
ASX:RHT's Cash-to-Debt is ranked worse than 53.73% of 670
companies
in the Healthcare Providers & Services industry
Industry Median: 0.785
vs ASX:RHT: 0.66
Resonance Health (ASX:RHT) Cash-to-Debt Explanation
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
Resonance Health Cash-to-Debt Related Terms
Resonance Health Cash-to-Debt Historical Data
* Premium members only.
The historical data trend for Resonance Health's Cash-to-Debt can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
ASX:RHT vs VEEV, BTSG, HQY: Cash-to-Debt Comparison
For the Health Information Services subindustry, Resonance Health's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Resonance Health Cash-to-Debt vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Resonance Health's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where Resonance Health's Cash-to-Debt falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Resonance Health (ASX:RHT) has a Cash-to-Debt of 0.66 as of Dec. 2025. This is 99% below median its historical median of 48.63. Over the past decade, Resonance Health's Cash-to-Debt has ranged from 0.66 to 10,000.00. According to the industry distribution chart, Resonance Health ranks #360 out of 670 companies in the Healthcare Providers & Services industry, placing it in the top 53.7%.
Is Resonance Health's Cash-to-Debt too high?
Resonance Health's current Cash-to-Debt of 0.66 is 99% below median its 10-year median of 48.63. Over the past 10 years, this metric has ranged from a low of 0.66 to a high of 10,000.00. The Healthcare Providers & Services industry median Cash-to-Debt is 0.79. Resonance Health's value of 0.66 is 15.9% below this industry median. Based on the distribution chart, Resonance Health ranks #360 out of 670 companies in the Healthcare Providers & Services industry, which is below the industry midpoint.
How does Resonance Health's Cash-to-Debt compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, Resonance Health ranks #360 out of 670 companies for Cash-to-Debt. This places Resonance Health in the lower half of its industry. The industry median Cash-to-Debt is 0.79. Resonance Health's value of 0.66 is 15.9% below this benchmark. Historically, Resonance Health's own Cash-to-Debt has ranged from 0.66 to 10,000.00 over the past decade. While the company's 10-year median is 48.63 vs. the industry median of 0.79, Resonance Health has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Healthcare Providers & Services company?
The median Cash-to-Debt among Healthcare Providers & Services companies is 0.79, based on 670 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Resonance Health's current Cash-to-Debt of 0.66 is 15.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Healthcare Providers & Services industry, the median Cash-to-Debt is 0.79 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Resonance Health's current Cash-to-Debt is 0.66, which is 99% below median its own 10-year median of 48.63. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Resonance Health stock overvalued right now?
Based on GuruFocus' analysis, Resonance Health (ASX:RHT) is currently considered Possible Value Trap. The stock's GF Value™ is A$0.12, compared to a current price of A$0.06 — trading 52.5% below its estimated fair value. The current Cash-to-Debt is 0.66, which is 99% below median its 10-year median of 48.63 and 15.9% below the Healthcare Providers & Services industry median of 0.79. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For Resonance Health (ASX:RHT), the current Cash-to-Debt is 0.66 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Resonance Health Ltd is engaged in the development and commercialisation of software-as-medical-device (SaMD) technologies and services for the quantitative analysis of radiological images in a regulated and quality-controlled environment. The Group's core SaMD product is FerriScan, a non-invasive liver analysis technology used for the assessment of iron in the liver. The Company also has several AI-assisted SaMDs including FerriSmart, HepaFatSmart, and LiverSmart. Its business segments are; SaMD1 which derives key revenue, Corporate, TrialsWest, and Resonance Clinica. Geographically, it generates maximum revenue from the Asia Pacific region and the rest from North America, and Europe, Middle East and Africa (EMEA) regions.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:RHT has been successfully added to your 
